Google DeepMind Unveils AlphaGenome 2 for Cell-Specific Genetic Predictions

What happened

Google DeepMind has unveiled AlphaGenome 2, a successor to AlphaGenome that predicts how genetic variants affect individual cell types and states. Trained on more than 100 million cell profiles across 68 tissues, it identified nearly twice as many variants that can change gene expression in cells as its previous state-of-the-art model, according to the company. Google says it is available today for non-commercial research through the AlphaGenome API, with a limited private preview for commercial research.

Read next

• More changes in today’s briefingGoogle DeepMind Introduces Gemini 4 Hydrogen for Fast Agentic Workflows

Reported by 6 sources

The story so far

Google DeepMind has released AlphaGenome 2, a model that predicts how DNA variants affect specific human cell types and states. The model is available through the AlphaGenome API for non-commercial research, while commercial research access is in a closed private preview. Google says it is intended for research and has not been validated or approved for clinical or diagnostic use. Google says AlphaGenome 2 was trained on more than 107 million cell profiles. On the TenK10K benchmark, it identified nearly twice as many causal variants as the original AlphaGenome; The Decoder reports about 30 percent for AlphaGenome 2 versus 16 percent for a fine-tuned AlphaGenome 1.